Skip to main content

Bladder cancer: types, risk factors, diagnosis, treatment and prevention: further clinical trials

Part 2 of 2
Published on September 30, 2026   37 min

A selection of talks on Clinical Practice

Please wait while the transcript is being prepared...
0:00
Hello. I'm Dr. Guru Sonpavde. I'm the GU oncology and phase one director at the Advent Health Cancer Istitute in Orlando, Florida. So I'm here to discuss bladder cancer, types, risk factors, diagnosis, treatment, and prevention. Welcome to Part 2 of my talk.
0:23
These are my disclosures.
0:27
Next we move on to the era of antibody-drug conjugates in the next slide. This shows you a drug called enfortumab vedotin. This is an antibody drug conjugate. This is an antibody backbone which targets nectin-4. It binds to nectin-4, which is a surface membrane protein overexpressed in urothelial carcinoma. This [inaudible] monoclonal antibody is conjugated to a toxin called monomethyl auristatin E, so MMAE.This is a tubulin toxin, very potent tubulin-disrupting chemotherapy essentially. So this agent was looked at early on in patients who are progressing post-chemotherapy and PD-L1 immune checkpoint inhibition and demonstrated a high response rate of approximately 40-45% as shown here.
1:21
So these data led to, on the next slide, the EV-301 trial where EV the enfortumab vedotin antibody drug conjugate, was compared versus historical chemotherapy, which was taxane or vinflunine, in patients in the third-line setting which is post-platinum and PD-1/L1 inhibitor-treated patients. As shown here, there was an improvement in survival, the survival median was 12.9 months for enfortumab vedotin versus 8.9 months for chemotherapy and these data with a hazard ratio of 0.7. These led to approval of enfortumab vedotin as therapy for post-platinum and PD-1/L1 inhibitor-treated patients.

Quiz available with full talk access. Request Free Trial or Login.

Show
Hide

Bladder cancer: types, risk factors, diagnosis, treatment and prevention: further clinical trials

Embed in course/own notes